Robeco Institutional Asset Management B.V. reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 19.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,565 shares of the company’s stock after selling 5,658 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Zoetis were worth $1,470,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Guardian Life Insurance Co. of America lifted its holdings in shares of Zoetis by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after acquiring an additional 13 shares during the period. Sii Investments Inc. WI lifted its holdings in shares of Zoetis by 0.3% during the 1st quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock worth $383,000 after acquiring an additional 23 shares during the period. Argent Trust Co lifted its holdings in shares of Zoetis by 0.8% during the 1st quarter. Argent Trust Co now owns 4,132 shares of the company’s stock worth $221,000 after acquiring an additional 32 shares during the period. Ironwood Investment Management LLC lifted its holdings in shares of Zoetis by 0.7% during the 2nd quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock worth $429,000 after acquiring an additional 48 shares during the period. Finally, Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Zoetis by 1.3% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 4,201 shares of the company’s stock worth $262,000 after acquiring an additional 55 shares during the period. Institutional investors and hedge funds own 93.31% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/07/zoetis-inc-zts-stake-decreased-by-robeco-institutional-asset-management-b-v.html.

Shares of Zoetis Inc. (NYSE:ZTS) opened at 63.39 on Thursday. The firm has a 50-day moving average of $61.75 and a 200 day moving average of $58.89. The firm has a market cap of $31.00 billion, a P/E ratio of 35.83 and a beta of 1.02. Zoetis Inc. has a 12 month low of $46.86 and a 12 month high of $63.85.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting analysts’ consensus estimates of $0.53. The company had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.49 earnings per share. On average, equities research analysts anticipate that Zoetis Inc. will post $2.34 EPS for the current fiscal year.

Several brokerages have recently weighed in on ZTS. Cantor Fitzgerald reiterated a “buy” rating and set a $75.00 price objective on shares of Zoetis in a report on Wednesday. Stifel Nicolaus reiterated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a report on Friday, September 1st. Piper Jaffray Companies set a $73.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a report on Friday, August 25th. Cowen and Company set a $70.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a report on Thursday, August 24th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $62.00 price objective on shares of Zoetis in a report on Monday, August 7th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company. Zoetis has an average rating of “Buy” and a consensus price target of $65.44.

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.